This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and medical directors. We explore how payers and physicians interact and how reimbursement decisions affect the prescribing and uptake of specific therapies at the brand level.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Key Drugs: Aranesp, Epogen, Procrit, Mircera, Retacrit, Auryxia, Roxadustat, Vadadustat, Daprodustat.
Key Companies: Amgen, Johnson & Johnson, Vifor Pharma, Roche, Pfizer, Akebia Therapeutics, FibroGen, AstraZeneca, GSK.